

Fibrocell Science, Inc.
Form 8-K
July 27, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF THE EARLIEST EVENT REPORTED): July 27, 2015

FIBROCELL SCIENCE, INC.
(Exact Name of Registrant as Specified in its Charter)

DELAWARE	001-31564	87-0458888
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

405 EAGLEVIEW BLVD., EXTON, PA 19341
(Address of principal executive offices and zip code)

(484) 713-6000
(Registrant's telephone number, including area code)
(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 – Other Events.

On July 27, 2015, Fibrocell Science, Inc. (“Fibrocell”) consummated its previously announced underwritten offering (the “Offering”) of Fibrocell’s common stock, par value \$0.001 per share (the "Common Stock"), which Offering is more fully described in Fibrocell’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2015. Fibrocell sold 2,974,136 shares of Common Stock in the Offering, which included the full exercise of the underwriters' over-allotment option. The net proceeds to Fibrocell from the sale of the Common Stock, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by Fibrocell, will be approximately \$15.7 million. Fibrocell intends to use the net proceeds for the continued clinical and preclinical development of its product candidates and for other general corporate purposes, which may include working capital, research and development expenditures, the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property, capital expenditures and general and administrative expenses.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

By: Fibrocell Science, Inc.
 /s/ Keith A. Goldan
 Keith A. Goldan
 SVP and Chief Financial Officer

Date: July 27, 2015